Safety And Tolerability Of A 10-mg Intravenous Bolus Sildenafil Dose In Patients With Pulmonary Arterial Hypertension And Comparison Of Its Pharmacokinetics With A 20-mg Oral Sildenafil Dose
Jean‐Luc Vachiéry(Erasmus Hospital), Robert Naeije(Erasmus Hospital), Xiang Gao(Qingdao University), Gary Layton(University of Geneva), Naoto Hayashi(Pfizer (United Kingdom)), Sandrine Huez(Erasmus Hospital), Hunter Gillies(Pfizer (United Kingdom))
Cited by 0
Related Papers
Contemporary Management of Acute Right Ventricular Failure: A Statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology
|European Journal of Heart Failure|2016|708
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study
|The Lancet|2014|488
High-Altitude Pulmonary Edema Is Initially Caused by an Increase in Capillary Pressure
|Circulation|2001|468
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension
|Circulation|2011|375
Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension
|CHEST Journal|2011|257